Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Phio PharmaceuticalsPHIO -2.70%28 3-Year EPS without NRI Growth Rate is 74.80% as of Jun. 2026, which is 15% above its 10-year median of 65.15. GuruFocus rates PHIO with a GF Score™ of 28/100. The stock has 2 warning signs investors should review. Among 1,160 Biotechnology companies, Phio Pharmaceuticals ranks better than 94.14% on this metric.
During the past 3 years, the average EPS without NRI Growth Rate was 74.80% per year.
During the past 5 years, the average EPS without NRI Growth Rate was 61.10% per year.
During the past 10 years, the average EPS without NRI Growth Rate was 66.70% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
During the past 13 years, the highest 3-Year average EPS without NRI Growth Rate of Phio Pharmaceuticals was 81.00% per year. The lowest was 37.90% per year. And the median was 65.15% per year.
Phio Pharmaceuticals (NAS:PHIO) 3-Year EPS without NRI Growth Rate Explanation
EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.
Phio Pharmaceuticals 3-Year EPS without NRI Growth Rate Related Terms
PHIO vs KALA, ANEB, GTBP: 3-Year EPS without NRI Growth Rate Comparison
For the Biotechnology subindustry, Phio Pharmaceuticals's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Phio Pharmaceuticals 3-Year EPS without NRI Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Phio Pharmaceuticals's 3-Year EPS without NRI Growth Rate distribution charts can be found below:
* The bar in red indicates where Phio Pharmaceuticals's 3-Year EPS without NRI Growth Rate falls into.
Phio Pharmaceuticals 3-Year EPS without NRI Growth Rate Calculation
This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
What does a 3-Year EPS without NRI Growth Rate of 74.80% mean?
Phio Pharmaceuticals (PHIO) has a 3-Year EPS without NRI Growth Rate of 74.80% as of Jun. 2026. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Phio Pharmaceuticals and its competitors. This is 15% above median its historical median of 65.15. Over the past decade, Phio Pharmaceuticals' 3-Year EPS without NRI Growth Rate has ranged from 37.90 to 81.00. According to the industry distribution chart, Phio Pharmaceuticals ranks #68 out of 1160 companies in the Biotechnology industry, placing it in the top 5.9%.
Is Phio Pharmaceuticals' 3-Year EPS without NRI Growth Rate too high?
Phio Pharmaceuticals' current 3-Year EPS without NRI Growth Rate of 74.80% is 15% above median its 10-year median of 65.15. Over the past 10 years, this metric has ranged from a low of 37.90 to a high of 81.00. The Biotechnology industry median 3-Year EPS without NRI Growth Rate is 16.05. Phio Pharmaceuticals' value of 74.80% is 366% above this industry median. Based on the distribution chart, Phio Pharmaceuticals ranks #68 out of 1160 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Phio Pharmaceuticals has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does Phio Pharmaceuticals' 3-Year EPS without NRI Growth Rate compare to KALA and ANEB?
According to the Biotechnology industry distribution chart, Phio Pharmaceuticals ranks #68 out of 1160 companies for 3-Year EPS without NRI Growth Rate. This places Phio Pharmaceuticals in the top 6% of its industry — outperforming the majority of peers. The industry median 3-Year EPS without NRI Growth Rate is 16.05. Phio Pharmaceuticals' value of 74.80% is 366% above this benchmark. Historically, Phio Pharmaceuticals' own 3-Year EPS without NRI Growth Rate has ranged from 37.90 to 81.00 over the past decade. While the company's 10-year median is 65.15 vs. the industry median of 16.05, Phio Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EPS without NRI Growth Rate for a Biotechnology company?
The median 3-Year EPS without NRI Growth Rate among Biotechnology companies is 16.05, based on 1,160 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EPS without NRI Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EPS without NRI Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Phio Pharmaceuticals's current 3-Year EPS without NRI Growth Rate of 74.80% is 366% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EPS without NRI Growth Rate mean?
A high 3-Year EPS without NRI Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Phio Pharmaceuticals and its competitors. For the Biotechnology industry, the median 3-Year EPS without NRI Growth Rate is 16.05 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Phio Pharmaceuticals's current 3-Year EPS without NRI Growth Rate is 74.80%, which is 15% above median its own 10-year median of 65.15. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Phio Pharmaceuticals stock overvalued right now?
Phio Pharmaceuticals (PHIO) has a current 3-Year EPS without NRI Growth Rate of 74.80%. The current 3-Year EPS without NRI Growth Rate is 74.80%, which is 15% above median its 10-year median of 65.15 and 366% above the Biotechnology industry median of 16.05. Phio Pharmaceuticals' overall GF Score™ is 28/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EPS without NRI Growth Rate calculated?
3-Year EPS without NRI Growth Rate is calculated from a company's financial statements. For Phio Pharmaceuticals (PHIO), the current 3-Year EPS without NRI Growth Rate is 74.80% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Phio Pharmaceuticals Corp is a clinical-stage biopharmaceutical company whose proprietary INTASYL small-interfering RNA gene silencing technology is designed to make immune cells more effective in killing tumor cells. Its pipeline programs are PH-762 and PH-894. The group is developing therapeutics that are designed to leverage INTASYL to precisely target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems. It is committed to discovering and developing cancer treatments for patients by creating new pathways toward a cancer-free future. The Company operates with a single operating segment, the Clinical segment, and all assets are located in the United States.
28GF Score
Get the complete analysis for PHIO
3-Year EPS without NRI Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PHIO has been successfully added to your 
